Data Sheet (Cat.No.TMAB-05973)

Anti-FEZ1 Polyclonal Antibody

Product Details

Ig Type:	IgG
Reactivity:	Mouse (predicted:Human,Rat,Dog,Pig,Cow,Horse,Rabbit,Sheep)
Molecular Weight:	Theoretical: 45 kDa. Actual: 45 kDa.
Purification:	Protein A purified

Applications

Verified Activity:	1. Paraformaldehyde-fixed, paraffin embedded (mouse cerebellum); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30 min; Antibody incubation with (FEZ1) Polyclonal Antibody, Unconjugated (TMAB-05973) at 1: 200 overnight at 4°C, followed by operating according to SP Kit (Rabbit) instructions and DAB staining. 2. Sample: Cerebrum (Mouse) Lysate at 40 µg Cerebellum (Mouse) Lysate at 40 µg Hippocampus (Mouse) Lysate at 40 µg Primary: Anti-FEZ1 (TMAB-05973) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 45 kD Observed band size: 45 kD
Application:	WB,IHC-P,IHC-Fr,IF
Recommended	WB: 1:500-2000; IHC-P: 1:100-500; IHC-Fr: 1:100-500; IF: 1:100-500

Properties

Stability & Storage:	Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	KLH conjugated synthetic peptide: human FEZ1
Antigen Species:	Human
Gene ID:	9638
Uniprot ID:	Q99689

Research Background

Frequent loss of heterozygosity (LOH) at human chromosome 8p22-p21 is associated with various tumors including prostate and breast cancer. The 8p22-p21 region contains the FEZ1 gene, which is altered in tumors of the esophagus, prostate and breast. The FEZ1 protein (also known as leucine zipper putative tumor suppressor or LZTS1) contains a DNA-binding leucine zipper motif. FEZ1 is expressed in normal breast and prostate, but alterations in FEZ1 expression result in abnormal cell growth. The absence of FEZ1 expression is characteristic of breast and

prostate cancer cell lines as well as primary breast and pro-state tumors. This absence of FEZ1 may be due to several factors, including mutations in the FEZ1 gene or hypermethylation of the CpG island flanking the FEZ1 promoter region. FEZ1 acts as a negative regulator of cell growth. During cell-cycle progression, FEZ1 localizes to microtubule components and is hyperphosphorylated by cAMP-dependent kinase.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481